Sponsor
Peking Union Medical College
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Peking Union Medical College appears in 29 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
29 shownReal-world First-line Sugemalimab-Chemotherapy in Advanced NSCLCNCT07247227 · lead sponsor · 2023-10-10
RECRUITINGNutrition Support on Outcomes and Cost-effectiveness for Patients at RiskNCT00289380 · lead sponsor · 2005-01-01
RECRUITINGEffectiveness and Cost-effectiveness of Digital Psychological Intervention (EmoEase) in Chinese COPD PatientsNCT06026709 · lead sponsor · 2025-10-01
NOT_YET_RECRUITINGImpact of Multi-Component Interventions on High Risk COPD PopulationNCT06456996 · lead sponsor · 2024-06-17
COMPLETEDImpact of Multi-component Interventions on Populations With Mental Health Symptoms and High-risk COPDNCT06458218 · lead sponsor · 2024-06-17
COMPLETEDImpact of Multi-Component Interventions on High-Risk COPD SmokersNCT06458205 · lead sponsor · 2024-06-17
COMPLETEDImpact of Multi-Component Intervention on Suspected Asthma PopulationNCT06457009 · lead sponsor · 2024-06-17
COMPLETEDChina Hypertension and Diabetes Care Cascade StudyNCT06141278 · lead sponsor · 2024-01-01
NOT_YET_RECRUITINGInetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM PathwayNCT04736589 · lead sponsor · 2021-02-02
NOT_YET_RECRUITINGNeoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer PatientsNCT04941417 · lead sponsor · 2020-11-24
UNKNOWNCorrelation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLCNCT05458726 · lead sponsor · 2020-09-15
UNKNOWNDacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLCNCT04768491 · lead sponsor · 2020-09-01
UNKNOWNSafety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural EffusionNCT04131231 · lead sponsor · 2019-10-15
UNKNOWNPegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast CancerNCT03994107 · lead sponsor · 2019-10-01
UNKNOWNClinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast CancerNCT03785704 · lead sponsor · 2019-01-01
UNKNOWNClinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid ModelNCT03544047 · lead sponsor · 2019-01-01
UNKNOWNClinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast CancerNCT03786575 · lead sponsor · 2018-12-01
UNKNOWNPyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast CancerNCT03412383 · lead sponsor · 2018-02-20
UNKNOWNFat Grafting Used for the Treatment of Breast Cancer Related Lymphedema in ChinaNCT02981485 · lead sponsor · 2016-12-01
UNKNOWNThe Study on the Clinical Utility of Liquid Biopsy in Breast CancerNCT02902991 · lead sponsor · 2016-06-01
UNKNOWNAI Prediction Model and Risk Stratification for Lung Metastasis in Colorectal CancerNCT05816902 · lead sponsor · 2016-01-01
COMPLETEDStudy on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 InfectionNCT02219672 · lead sponsor · 2014-07-01
UNKNOWNRaltegravir-based Antiretroviral Therapy for Resistant HIV-1 InfectionNCT01844310 · lead sponsor · 2013-05-01
UNKNOWNEfficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral TherapyNCT01844297 · lead sponsor · 2013-05-01
UNKNOWNStudy on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS PatientsNCT00872417 · lead sponsor · 2009-03-01
UNKNOWNThe Chinese Mutation Hotspot of ENaC Causing Liddle's Syndrome and the Association of ENaC Variations and HypertensionNCT00448162 · lead sponsor · 2005-05-01
SUSPENDEDThree Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation CohortNCT00618176 · lead sponsor · 2005-01-01
COMPLETEDEnvironmental Pollutants and Neurological DisordersNCT07140601 · collaborator · 2025-08-01
RECRUITINGXishui Project for IDM of COPD and ComorbiditiesNCT06456749 · collaborator · 2024-06-17
UNKNOWNDrugs studied in this sponsor's trials
5 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Peking Union Medical College as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
dacomitinib1
osimertinib1
paclitaxel1
sirolimus1
trastuzumab1
dacomitinib RxCUI 2058849 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
osimertinib RxCUI 1721560 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
sirolimus RxCUI 35302 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
trastuzumab RxCUI 224905 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor27
collaborator2
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.